AB Softメーカーiiの使用説明書/サービス説明書
ページ先へ移動 of 36
The Brie f Pain Inv ento ry User Gu ide Char les S. Cleelan d, P hD ii C opyright and T e r m s of Us e The B rie f Pain In vento ry (BPI) copy r igh t is held by Dr. C harles S. Cleelan d (19 91) . The c opyrig ht appl ies to t he BPI a nd all it s der iv at ives in any l ang u age.
i Tab l e of Co n ten ts C hap te r 1 ... ....... ....... ....... ........ ....... ....... .... ....... ....... . 1 D evel opm ent o f th e Br ie f P a in In ven tor y ...... ....... . 1 Ba ckgr ound ..... ....... ....... ....... ........ ....... ....
1 Chapt er 1 De ve l op m en t o f th e Br ie f P a in I nven tor y The B rie f Pain In vento ry ( BPI) h as beco me one of the most w i d ely use d measur ement t ools for asse ssing cl inical p ain.
3 would b e e asil y tra nslate d for no n-Engl ish- spea k ing p atients; a n d (e) w ou ld cap t ure no t only pai n sev erity, b ut also the p e r ception of how pai n inte rfe red with daily life .
5 E arl y V ersi on : T he Wis c onsi n Bri ef Pai n Q ues ti onn ai re The fi r st v ersion of ou r pain measu re was the Wi sconsi n B r ief Pai n Question nair e (BPQ ; Daut & Cleelan d, 1982 ; Daut , Cleel and, & Fla nery , 1983 ) .
7 in cl i n ical and r esear ch a ppl icatio ns. The shor t form is t yp i c all y wha t is ref erre d to when the BPI is ci ted in researc h, a nd it is the ve rsio n we descri be b elow . Most p sychome tric e va luatio ns of the BPI have b een perf orme d on the short form.
9 from 8 0 cent e r s were enr olled i n t h e study (Cleela nd e t al., 199 4). Fact o r analys i s v er i fie d the tw o separat e factors, pain se v er ity an d interf e r ence, found in th e pre v ious study . Int ern al s tabilit y (Cr o nb a c h al pha ) was also examin ed in this stu dy .
11 Tes t-Retes t Reliab ility and A lternate-Fo rms Reli ability : the H indi T ran sla tio n Finall y, one st udy comb ine d an e xaminat i on of bot h t est-ret est rel i ab i l i t y and alt ernate-f orms rel iab i lity (Saxena et al .
13 cl in ical t rial s: IMMPAC T rec o mm endation s. J P a in 9 (2): 105 - 1 21, 2/200 8. Food and Dru g Administr ation. Gui deline s for Indust ry (draft ). Pat ient-R epor ted Out c om e Mea s ur es: Use in Med ic al Prod u ct Deve lopmen t to Supp ort Label ing Claims.
15 Chapt er 2 BPI Ref erenc e s: Use of the B P I in Various St udies The Brief Pai n Inve ntory ha s been u sed in more tha n 40 0 studi es wo rldwi de. Here we pre sen t BPI refer ences cat egor iz e d b y typ e of stud y . Can cer Bo ne P ai n ....
17 indu ced pain flar e after pall iat ive r a d ioth er apy for bone met astases-a pilot st udy. Sup port Care Canc e r 15 (6): 643-647 , 6/20 07. 8. Cleel and CS. The m easurem e nt of pai n from m e t astatic bone d iseas e: capt uring t he patient' s exper i e nce.
19 met ast ases i n can cer pat ients]. Nippon Iga ku Hosha sen Gakk ai Zassh i 65(4 ): 399-410 , 10/200 5. 24. Pi stevo u-Gomp aki K, Kou lou l ias V E, V arv eris C, Mystak idou K, Georga kop o ulos G, E l efthe r iadi s N, Gompaki s N, Ko uva ris J.
21 9. Holtan A, A ass N , Nordoy T, Haugen DF , Ka asa S , Moh r W, Ko n g s ga ard UE. Pre valen c e o f pain in hosp italised cancer pat i e nts in Nor way: a nat ional sur vey. P all i a t Med 21(1 ): 7-13, 1/20 07. 10. Kong sg aard UE, Holta n A, Aa ss N.
23 Cooperat iv e On cology Gr oup. Ann Oncol 16( 6) : 972-98 0, 6/20 05. 11. Du Pen SL, Du Pe n AR, Po lissa r N, Ha nsbe rry J, K raybi ll BM, Sti llma n M, Panke J, Ev erly R, Syrj ala K. I mple menti ng gu i d elines for can cer p ain mana gement : r esults of a r andomiz e d controlled clinical trial.
25 28. Li ang SY , Ya t e s P, Edwa rds H, Ts ay SL. Facto r s in fluenci ng op io id -ta k ing self-eff i c ac y and an alg esic adh erence in Ta iwa nese outp atients with ca ncer.
27 mor ph i n e p r e -t re ated an d o pioid naive pat ients w ith tr ansdermal f entanyl. Int J Ca ncer 1 07(3 ): 4 86-49 2, 11 /2003. 46. Mysta k id ou K, Par pa E, Kat souda E, Galanos A, V l ahos L . Influ ence o f p a in and q uali t y of life on desir e for hasten ed death in patie nts wi th adv an c ed cance r.
29 popula tion o f men w ith pros tate cance r. B r J Cance r 85(4) : 497-50 3, 8/2001. 62. Sa ndb l om G , Carlss on P, Sennf alt K , V arenho rst E. A populatio n-base d study of pai n and quali ty of l i fe during the year befor e d e ath in m en wi t h prost ate can cer.
31 Depressive Disorders 1. Bran nan SK, Ma llinck r odt CH, B rown EB, Woh lreich M M, Watk in JG, Scha tzbe rg AF . Dulox e ti ne 6 0 mg once -dai ly in the tr e atm ent of painful physical symptom s in pat ients w i t h major dep r ess iv e dis ord er .
33 7. Schif f m an n R, K opp JB , Austin H A, II I, Sabni s S, Moore D F, Weibel T, Ba low JE, B rady RO . Enzyme r eplace ment the rapy i n Fa bry dis ea se: a ran dom ize d co ntr oll ed t r ial. JA MA 285 (21 ): 2743 -2749 , 6/2001. F ibro mya lgia 1.
35 8. New shan G, L e fko w itz M. Tran sderm al fent anyl f o r chronic pain in AIDS: a pi l o t stu dy. J Pain Symp tom Manage 21 (1): 69- 77, 1/20 01 .
37 8. Chae J , Masc aren has D , Yu D T, Ki rstein s A, E lovi c EP, F lan agan SR , Harv ey RL, Zo rowit z RD, F ang ZP. Pos tstro ke shou lder pain : its re lati onshi p to motor i mpa i rmen t, ac tiv i t y limi ta tio n, and qual i ty of life. A r ch Ph ys Med Rehab i l 88(3 ) : 298-30 1, 3 / 200 7.
39 28. Renzen brink G J, IJz erman MJ. Per cutaneo us ne uromus cular electr i cal stimulation (P-NMES) for tr eating shoulde r pain in chro nic he miplegi a. Ef fects on sho ulde r pai n and qu ality of l i fe. Cl in Rehab i l 18(4 ) : 359-3 65, 6/2004.
41 val pro ate in p at ients with can cer-r e l at ed neuro pathic pain. J Pa i n Symptom M ana ge 21(3 ) : 204 -209, 3 / 20 01. 9. Katz N P, G ammaito ni AR, Da vis MW, Dwo rkin R H.
43 5. Cowan DT, Wi lson-B arne tt J, Griffi ths P , Vau ghan DJ , Gon dhia A, Allan LG. A random ized, double-b l ind, placebo-controlled, cro ss-over pilot study to asse s s the eff ects of long-t e rm op ioid drug co nsum pti on and sub se quent a bs tine nce i n ch roni c non c a ncer pa in pat ients r eceiving controll e d-releas e morph i n e.
45 fi nd ings f ro m a pi lo t study. J Opioid Manag 3(3) : 145-154 , 5/20 07. 22. Thi e NM , Pras ad NG, Ma jor PW. Ev aluatio n of glucos amin e sulf ate com pared t o ibupro fen fo r the tre atm e nt o f tem porom and i b ular joint osteoart hrit is: a ran do m ized doubl e bli nd contro lled 3 month clin ica l tri al.
47 5. Da v ison SN. P ain in hem odial y sis pat ients: pre val ence, cau se, se ve r ity, an d mana gement . A m J Ki dne y Di s 42(6 ): 1239 -1247, 12/2 003. 6. Dell D D, We ave r C, Ko zempel J , Ba rsevi ck A. Re cove ry af t e r tr ansverse r ectus abdom inis m y ocutan eous flap brea st r econ stru ct io n sur gery.
49 placebo-c ontrolled clinical trial. J E p id em io l B ios t a t 5(6 ): 359- 365, 2000. 23. Ti ttle MB, M cM i llan SC, Hag an S. V alid ating the brief pain inve n tory f or use wit h surgical patient s with can cer. Oncol Nur s Fo rum 30 (2): 325 - 330, 3/2003.
51 acute onc ol og y settin g . A sia-Pa cific Journ al of Clinical Onc o l ogy 3(2 ) : 8 9-94, 6/20 07. 12. Cleelan d CS, Ry an KM. Pain a ssessment: glob a l use of th e Brief Pain In v en t ory. A nn Acad Med Singap ore 23(2 ): 129-1 38 , 3/19 94. 13.
53 To o l s: Is th e Conte nt Appr opr iate f or Us e in Palli at ive Care ? J Pa i n Symptom M ana ge 32(6 ) : 567 -580, 12 / 2 006. 29. J anjan N A, Payn e R , Gilli s T, Podolo ff D, Libshi tz HI, Lenzi R, Ther iault R, M art in C, Ya sko A. Pre senting sym ptoms in pat ients r e ferr ed to a m ultid is ciplinar y c l inic for bone m etast ases.
55 the t i m e tr ade- o ff. Jour nal of Cl inical E pid em iol ogy 60 ( 10 ): 1029 -1033 , 10/2007. 46. Ra dbruch L, Lo i ck G, Kie ncke P, Lin dena G, S abatow ski R , Gr ond S, Lehm ann KA , Cl e eland CS . V al idat i o n of t he Germ an v er sion of th e Br i ef P ain Inventor y .
57 osteoa rth r i tic pain. J Pai n Symptom M anage 3 1(1): 48-5 7, 1/20 06. 64. Wu EQ , B orton J , Sai d G, Le TK, Mon z B, Rosi l io M, Avo inet S. Estim ated pre valen ce of p eripheral neur op at hy and asso ciated p a i n i n adult s with diab ete s in F r ance.
59 9. U ki J, Me ndo za T , Cl eel and C S, Na kam ura Y , T ake da F. A br ief can cer pa i n a ssessment tool i n Japan ese: the uti l ity of t he Jap a n e se Br ief P ain In v en t ory--B PI-J. J Pa in Sym ptom Mana ge 16(6): 364-37 3, 12 / 1998. 10.
61 16. Cleelan d CS. Measurem ent a nd pr ev al ence of pain i n can cer. Sem i n O ncol N urs 1(2 ): 87-92 , 5/1985. 17. Cle ela nd CS. How to t r e at a " cons truc t " . J Pai n Sympt om Ma nage 1(3 ) : 16 1-162, 1986. 18. Cleelan d CS, Lad i n sky JL, Serli n RC, Nugy en CT.
63 BR, Stauffe r JW , vo n ST, W hi t e RE, Wi tt er J, Z avis i c S. Int erpretin g th e cl inical imp ortanc e o f treatm ent ou tco m es in chro nic pai n cli nica l trials : IMM P ACT rec ommendati ons . J Pai n 9(2) : 105-121 , 2/2008 . 35. Ewi ng G, Todd C, Rogers M, Barc lay S, M cCabe J , Ma r tin A.
65 51. Li KK, Harri s K, Hadi S, C how E. What s h ou ld be the op tima l cut po int s for m ild, moderat e, and se vere pain ? J ournal of Pall i at iv e Medic i ne 10(6 ) : 1338 - 1 346, 12/200 7.
67 69. Ta n G, J ense n MP, Tho rnby JI, Sh anti BF. V a lidati on of t he Bri ef Pai n In v entory f or chro nic nonmalig nant pain. J Pai n 5(2): 133- 137, 3/2004. 70. Yun YH, P a rk YS , Lee E S , Bang S M , Heo DS, Park S Y, Yo u CH, Wes t K. Vali dati o n of the Ko r ean ve r sion of t he EO RTC Q LQ- C30.
デバイスAB Soft iiの購入後に（又は購入する前であっても）重要なポイントは、説明書をよく読むことです。その単純な理由はいくつかあります：
AB Soft iiをまだ購入していないなら、この製品の基本情報を理解する良い機会です。まずは上にある説明書の最初のページをご覧ください。そこにはAB Soft iiの技術情報の概要が記載されているはずです。デバイスがあなたのニーズを満たすかどうかは、ここで確認しましょう。AB Soft iiの取扱説明書の次のページをよく読むことにより、製品の全機能やその取り扱いに関する情報を知ることができます。AB Soft iiで得られた情報は、きっとあなたの購入の決断を手助けしてくれることでしょう。
AB Soft iiを既にお持ちだが、まだ読んでいない場合は、上記の理由によりそれを行うべきです。そうすることにより機能を適切に使用しているか、又はAB Soft iiの不適切な取り扱いによりその寿命を短くする危険を犯していないかどうかを知ることができます。
ですが、ユーザガイドが果たす重要な役割の一つは、AB Soft iiに関する問題の解決を支援することです。そこにはほとんどの場合、トラブルシューティング、すなわちAB Soft iiデバイスで最もよく起こりうる故障・不良とそれらの対処法についてのアドバイスを見つけることができるはずです。たとえ問題を解決できなかった場合でも、説明書にはカスタマー・サービスセンター又は最寄りのサービスセンターへの問い合わせ先等、次の対処法についての指示があるはずです。
